menu
    • menu
    [{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"TerSera Canada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"TerSera Canada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"TerSera Canada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TerSera Canada \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Entinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Goserelin Acetate

    Menu

    Goserelin Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TerSera Canada

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            TerSera Canada

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Goserelin Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Health Canada Approves ZOLADEX LA for ER-Positive Breast Cancer in Premenopausal Women

                            Details : Health Canada has approved a sNDA for ZOLADEX LA (goserelin acetate), GnRH agonist at 10.8mg every 12 weeks for the management of ER+ early breast cancer in pre- and perimenopausal women.

                            Product Name : Zoladex

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            July 05, 2024

                            Lead Product(s) : Goserelin Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            German Wound Congress
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribociclib,Anastrozole,Goserelin Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novartis Kisqali® Prolonged PFS Benefit for Pre- and Perimenopausal Patients with Aggressive HR+/HER2− Meta...

                            Details : Kisqali (ribociclib) is the only CDK4/6 inhibitor with proven overall survival benefit across all three pivotal Phase III advanced breast cancer trials and is recognized as the only CDK4/6i with overall survival benefit in first-line HR+/HER2- advanced b...

                            Product Name : Kisqali

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 12, 2022

                            Lead Product(s) : Ribociclib,Anastrozole,Goserelin Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Syndax Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Syndax Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entinostat,Exemestane,Goserelin Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat + Exemestane in H...

                            Details : The trial did not achieve the primary endpoint of demonstrating a statistically significant overall survival (OS) benefit over hormone therapy alone.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 21, 2020

                            Lead Product(s) : Entinostat,Exemestane,Goserelin Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            German Wound Congress
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribociclib,Goserelin Acetate,Tamoxifen Citrate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Astex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novartis' KISQALI® (ribociclib) UPs Overall Survival in Pre- and Perimenopausal Women with HR+/HER2- Advanced...

                            Details : KISQALI® is the first CDK4/6 inhibitor to show statistically significant improvement in overall survival (key secondary endpoint) in advanced breast cancer in pre- and perimenopausal women.

                            Product Name : Kisqali

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 11, 2020

                            Lead Product(s) : Ribociclib,Goserelin Acetate,Tamoxifen Citrate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Astex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth